Peptides and Heparin Market
授權報價
| Single User License | $4,500 USD |
| Multiple User License | $5,500 USD |
| Custom Research License | $8,000 USD |
完整報告名稱與涵蓋範圍
Peptides and Heparin Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Peptides, Heparin), By Application (Oncology, Metabolic Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, Anticoagulation Therapy, Others), By Route of Administration (Injectable, Oral, Others), By End User (Hospitals and Clinics, Research Institutes and Laboratories, Pharmaceutical and Biotechnology Companies, Others), By Region & Competition, 2021-2031F
報告摘要
Market Overview
The global market for peptides and heparin is projected to expand significantly, rising from USD 13.41 billion in 2025 to USD 21.72 billion by 2031, reflecting an 8.37% compound annual growth rate. Peptides, defined as short chains of amino acids, regulate specific biological activities, while heparin is a crucial sulfated glycosaminoglycan serving as an anticoagulant. This growth is predominantly fueled by the increasing worldwide incidence of chronic metabolic and cardiovascular diseases, which demand continuous therapeutic solutions. For instance, the International Diabetes Federation estimated that 589 million adults would be living with diabetes globally in 2025, directly boosting the need for peptide-based treatments. Technological progress in chemical synthesis has also enhanced the stability and bioavailability of these therapeutics, broadening their clinical utility. However, market expansion faces a substantial hurdle in the form of a fragile supply chain, particularly for heparin's raw materials. The heavy reliance on porcine intestinal mucosa renders production vulnerable to disruptions from livestock diseases and contamination, creating potential manufacturing bottlenecks and supply shortages that could restrict the availability and distribution of these essential medications.
Market Driver
The escalating prevalence of cardiovascular and metabolic diseases serves as a primary driver for the peptides and heparin market. The success of Glucagon-like Peptide-1 (GLP-1) receptor agonists, which are peptide-based biologics offering effective glycemic control and weight reduction, has particularly spurred growth in the peptide sector, requiring expanded manufacturing. Novo Nordisk's financial report for 2024 showed a 25% increase in Diabetes and Obesity care sales, largely due to GLP-1 demand, underscoring peptides' vital role in managing metabolic conditions. Concurrently, the rising occurrence of coagulation disorders and thromboembolic events sustains the demand for heparin as an essential anticoagulant, especially in critical care. The International Society on Thrombosis and Haemostasis highlighted in October 2024 that one in four global deaths are linked to thrombosis-related conditions, emphasizing this continuous need. Furthermore, regulatory support for innovation is robust, with peptide and nucleic acid-based therapies accounting for roughly 10% of new FDA drug approvals in recent years, according to BioSpace in January 2025, signaling a strong pipeline.
Market Challenge
The primary impediment to the global peptides and heparin market's growth is the unstable supply chain, specifically its heavy dependence on porcine intestinal mucosa for heparin production. Since heparin almost exclusively uses animal-derived raw materials, the industry is highly susceptible to volatility caused by livestock diseases and trade disruptions. Outbreaks of such diseases immediately reduce the availability of healthy porcine mucosa, creating bottlenecks in Active Pharmaceutical Ingredient (API) manufacturing. This scarcity elevates procurement costs and limits the volume of finished drugs, thereby capping market expansion despite rising patient needs. Consequently, manufacturers struggle to maintain consistent inventory, leading to supply instability that hinders both revenue generation and reliable drug distribution. These interruptions prevent the market from fully capitalizing on the increasing prevalence of cardiovascular conditions. The severity of these supply issues is evident in figures from the American Society of Health-System Pharmacists, which reported 214 active drug shortages in Q3 2025, with heparin remaining a persistently difficult sterile injectable to source due to ongoing raw material and manufacturing vulnerabilities.
Market Trends
The market is undergoing a significant transformation with the shift towards oral peptide delivery systems, aiming to overcome the traditional reliance on injections for chronic metabolic conditions. Developers are incorporating advanced permeation enhancers and stabilizing technologies to improve the bioavailability of oral therapeutics, thereby addressing patient adherence challenges. This move towards non-invasive administration is supported by clinical successes in obesity management, such as Viking Therapeutics' August 2025 Phase 2 VENTURE trial, where oral VK2735 achieved up to 12.2% weight loss, demonstrating its competitive efficacy against injectable alternatives. Simultaneously, the development of Peptide Drug Conjugates (PDCs) for targeted oncology is expanding the market's therapeutic scope beyond metabolic and cardiovascular diseases. PDCs employ small peptide moieties to precisely deliver cytotoxic payloads, offering superior tissue penetration and faster clearance than larger antibody-drug conjugates. This approach is gaining traction for its potential to minimize systemic toxicity while maximizing potency against solid tumors, as evidenced by Bicycle Therapeutics' January 2025 Phase 1 Duravelo-1 trial, which reported a 65% overall response rate in metastatic urothelial cancer patients treated with zelenectide pevedotin.
Key Market Players
* Eli Lilly and Company
* Novo Nordisk A/S
* Sanofi S.A.
* Pfizer Inc.
* Takeda Pharmaceutical Co Ltd.
* Teva Pharmaceutical Industries Ltd.
* Abbott Laboratories
* Biofer SpA
* Cipla Limited
* Aspen Pharmacare Holdings Limited
Report Scope
In this report, the Global Peptides and Heparin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
# Peptides and Heparin Market, By Type
* Peptides
* Heparin
# Peptides and Heparin Market, By Application
* Oncology
* Metabolic Diseases
* Cardiovascular Diseases
* Neurological Disorders
* Infectious Diseases
* Anticoagulation Therapy
* Others
# Peptides and Heparin Market, By Route of Administration
* Injectable
* Oral
* Others
# Peptides and Heparin Market, By End User
* Hospitals and Clinics
* Research Institutes and Laboratories
* Pharmaceutical and Biotechnology Companies
* Others
# Peptides and Heparin Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Peptides and Heparin Market.
Available Customizations:
Global Peptides and Heparin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).
目錄 Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Peptides and Heparin Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (Peptides, Heparin)
5.2.2. By Application (Oncology, Metabolic Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, Anticoagulation Therapy, Others)
5.2.3. By Route of Administration (Injectable, Oral, Others)
5.2.4. By End User (Hospitals and Clinics, Research Institutes and Laboratories, Pharmaceutical and Biotechnology Companies, Others)
5.2.5. By Region
5.2.6. By Company (2025)
5.3. Market Map
6. North America Peptides and Heparin Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Application
6.2.3. By Route of Administration
6.2.4. By End User
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Peptides and Heparin Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Application
6.3.1.2.3. By Route of Administration
6.3.1.2.4. By End User
6.3.2. Canada Peptides and Heparin Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Application
6.3.2.2.3. By Route of Administration
6.3.2.2.4. By End User
6.3.3. Mexico Peptides and Heparin Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Application
6.3.3.2.3. By Route of Administration
6.3.3.2.4. By End User
7. Europe Peptides and Heparin Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Application
7.2.3. By Route of Administration
7.2.4. By End User
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Peptides and Heparin Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Application
7.3.1.2.3. By Route of Administration
7.3.1.2.4. By End User
7.3.2. France Peptides and Heparin Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Application
7.3.2.2.3. By Route of Administration
7.3.2.2.4. By End User
7.3.3. United Kingdom Peptides and Heparin Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Application
7.3.3.2.3. By Route of Administration
7.3.3.2.4. By End User
7.3.4. Italy Peptides and Heparin Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Application
7.3.4.2.3. By Route of Administration
7.3.4.2.4. By End User
7.3.5. Spain Peptides and Heparin Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Application
7.3.5.2.3. By Route of Administration
7.3.5.2.4. By End User
8. Asia Pacific Peptides and Heparin Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Application
8.2.3. By Route of Administration
8.2.4. By End User
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Peptides and Heparin Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Application
8.3.1.2.3. By Route of Administration
8.3.1.2.4. By End User
8.3.2. India Peptides and Heparin Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Application
8.3.2.2.3. By Route of Administration
8.3.2.2.4. By End User
8.3.3. Japan Peptides and Heparin Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Application
8.3.3.2.3. By Route of Administration
8.3.3.2.4. By End User
8.3.4. South Korea Peptides and Heparin Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Application
8.3.4.2.3. By Route of Administration
8.3.4.2.4. By End User
8.3.5. Australia Peptides and Heparin Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Application
8.3.5.2.3. By Route of Administration
8.3.5.2.4. By End User
9. Middle East & Africa Peptides and Heparin Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Application
9.2.3. By Route of Administration
9.2.4. By End User
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Peptides and Heparin Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Application
9.3.1.2.3. By Route of Administration
9.3.1.2.4. By End User
9.3.2. UAE Peptides and Heparin Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Application
9.3.2.2.3. By Route of Administration
9.3.2.2.4. By End User
9.3.3. South Africa Peptides and Heparin Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Application
9.3.3.2.3. By Route of Administration
9.3.3.2.4. By End User
10. South America Peptides and Heparin Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Application
10.2.3. By Route of Administration
10.2.4. By End User
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Peptides and Heparin Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Application
10.3.1.2.3. By Route of Administration
10.3.1.2.4. By End User
10.3.2. Colombia Peptides and Heparin Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Application
10.3.2.2.3. By Route of Administration
10.3.2.2.4. By End User
10.3.3. Argentina Peptides and Heparin Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Application
10.3.3.2.3. By Route of Administration
10.3.3.2.4. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Peptides and Heparin Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Eli Lilly and Company
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Novo Nordisk A/S
15.3. Sanofi S.A.
15.4. Pfizer Inc.
15.5. Takeda Pharmaceutical Co Ltd.
15.6. Teva Pharmaceutical Industries Ltd.
15.7. Abbott Laboratories
15.8. Biofer SpA
15.9. Cipla Limited
15.10. Aspen Pharmacare Holdings Limited
16. Strategic Recommendations
17. About Us & Disclaimer
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 TechSci Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們